To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
SEP agrees $1bn venture exit
British venture capital firm Scottish Equity Partners will sell BioVex, a company developing cancer treatments, to US trade buyer Amgen.
